Who is the top 10 BP in FimaNac (a theory!!) 2
Hi
Earlier I started this but now is in Archive. https://forum.hegnar.no/archive/thread/2435820/view
we will continue the discussion here:
If we assume that AstraZeneca is our top 10 big pharma within FimaNAc collaboration, then the following might be of interest.
First look at page 24 from Pci Biotech June 2018 presentation. The page has a table with the Nucleic acids successfully delivered by fimaNAC, pay particular attention to the last nucleic acid "AAV vector" (Link: http://pcibiotech.no/wp-content/uploads/2014/01/PCI-Biotech-Company-presentation-June-2018.pdf)
on 10/07/2018 AstraZeneca and 4D MOLECULAR THERAPEUTICS announced the following:
https://www.4dmoleculartherapeutics.com/medimmune-and-4d-molecular-therapeutics-collaborate-to-design-develop-and-commercialize-aav-gene-therapy-for-chronic-lung-disease/
if we read the message carefully,
“The collaboration will leverage 4DMT’s expertise in vector discovery and engineering, optimization and process development. MedImmune will conduct product development beginning from early clinical stages, drawing on the company’s extensive expertise in respiratory science.”
It seems this will start in clinical stages, meaning pre-clinical collaboration is over, is it a coincidence that our FimaNAc collaboration was extended a month earlier?. is it easy to assume that we are in collaboration with AstraZeneca where FimaNAc will be the mean of delivery for the AAV nucleic Acid? May be ! :)
Earlier I started this but now is in Archive. https://forum.hegnar.no/archive/thread/2435820/view
we will continue the discussion here:
If we assume that AstraZeneca is our top 10 big pharma within FimaNAc collaboration, then the following might be of interest.
First look at page 24 from Pci Biotech June 2018 presentation. The page has a table with the Nucleic acids successfully delivered by fimaNAC, pay particular attention to the last nucleic acid "AAV vector" (Link: http://pcibiotech.no/wp-content/uploads/2014/01/PCI-Biotech-Company-presentation-June-2018.pdf)
on 10/07/2018 AstraZeneca and 4D MOLECULAR THERAPEUTICS announced the following:
https://www.4dmoleculartherapeutics.com/medimmune-and-4d-molecular-therapeutics-collaborate-to-design-develop-and-commercialize-aav-gene-therapy-for-chronic-lung-disease/
if we read the message carefully,
“The collaboration will leverage 4DMT’s expertise in vector discovery and engineering, optimization and process development. MedImmune will conduct product development beginning from early clinical stages, drawing on the company’s extensive expertise in respiratory science.”
It seems this will start in clinical stages, meaning pre-clinical collaboration is over, is it a coincidence that our FimaNAc collaboration was extended a month earlier?. is it easy to assume that we are in collaboration with AstraZeneca where FimaNAc will be the mean of delivery for the AAV nucleic Acid? May be ! :)
Redigert 21.01.2021 kl 03:30
Du må logge inn for å svare
-
«
- 1
- 2 »
Stock DZ
24.07.2018 kl 20:57
9649
Forgot to mention: MedImmune is the global biologics research and development arm of AstraZeneca
Redigert 20.01.2021 kl 23:38
Du må logge inn for å svare
Takk TS. Vet ikke om det er AZ. Forventer selv at det er linket til en av styreverv aktiviteter av en styremedlem eller Scientific Advisory Committee. Er AZ nevnt?
Redigert 20.01.2021 kl 23:38
Du må logge inn for å svare
Flottesen
24.07.2018 kl 22:10
9525
AZ er i år på topp på "Pharmaceutical innovation index", så de er ikke fremmed for å tenke nytt:
http://ideapharma.com/pii
http://fortune.com/2018/03/28/astrazeneca-tops-drug-innovation-ranking/
http://ideapharma.com/pii
http://fortune.com/2018/03/28/astrazeneca-tops-drug-innovation-ranking/
Redigert 20.01.2021 kl 23:38
Du må logge inn for å svare
Flottesen
24.07.2018 kl 22:19
9496
Stockowner, styremedlem Andrew Hughes kommer fra AstraZeneca.
Redigert 20.01.2021 kl 23:38
Du må logge inn for å svare
Merlin
24.07.2018 kl 22:23
9484
Jeg skal vel i hvert fall ikke klage. Har kjempeavkastnig de siste årene, bare ved å følge enkle prinsipper: Gear up når det ser bra ut!
Den som intet våger osv.
Mitt aller beste forslag:
Nano Nano Nano. Hvorfor? Nano HAR ALLEREDE bevist at de har et kjempeprodukt! 1) Enkel administrasjon, 2) Fantastisk målstyrt effektiv virkning, 3) Stort marked.
Blir som Algeta kjøpt opp meget raskt til en høy pris!'
Nest best:
PCIB
Hvorfor? Banebrytende teknologi! Kan få kreftvaksiner til å virke 100 ganger bedre enn i dag. Nok for min del! Heller ikke så langt frem. Og bile duct cancer i tillegg!!
Neste på min liste : (Mange ganger bedre enn Norsk Hydro eller Yara for å si det slik!)
Photocure!
Et utrolig potensiale! Faktisk enig med focuss der! Men da må den nye CEO-en forstå hvordan man skal overbevise amerikanske urologer. Det har IKKE nåværende ledelse og salgskorps fått til. Jeg håper virkelig den nye lederen har alle tryllestavevner som behøves. Skulle egentlig ikke være så vanskelig? Med DE referansene, inklusive fra AUA og Medicare. Kanskje kan 1900-målet til focuss smelle inn etter hvert?
Den som intet våger osv.
Mitt aller beste forslag:
Nano Nano Nano. Hvorfor? Nano HAR ALLEREDE bevist at de har et kjempeprodukt! 1) Enkel administrasjon, 2) Fantastisk målstyrt effektiv virkning, 3) Stort marked.
Blir som Algeta kjøpt opp meget raskt til en høy pris!'
Nest best:
PCIB
Hvorfor? Banebrytende teknologi! Kan få kreftvaksiner til å virke 100 ganger bedre enn i dag. Nok for min del! Heller ikke så langt frem. Og bile duct cancer i tillegg!!
Neste på min liste : (Mange ganger bedre enn Norsk Hydro eller Yara for å si det slik!)
Photocure!
Et utrolig potensiale! Faktisk enig med focuss der! Men da må den nye CEO-en forstå hvordan man skal overbevise amerikanske urologer. Det har IKKE nåværende ledelse og salgskorps fått til. Jeg håper virkelig den nye lederen har alle tryllestavevner som behøves. Skulle egentlig ikke være så vanskelig? Med DE referansene, inklusive fra AUA og Medicare. Kanskje kan 1900-målet til focuss smelle inn etter hvert?
Redigert 20.01.2021 kl 23:38
Du må logge inn for å svare
Merlin
24.07.2018 kl 22:26
9474
Jeg undervurderer dog ikke:
If we assume that AstraZeneca is our top 10 big pharma within FimaNAc collaboration, then the following might be of interest.
First look at page 24 from Pci Biotech June 2018 presentation. The page has a table with the Nucleic acids successfully delivered by fimaNAC, pay particular attention to the last nucleic acid "AAV vector" (Link: http://pcibiotech.no/wp-content/uploads/2014/01/PCI-Biotech-Company-presentation-June-2018.pdf)
on 10/07/2018 AstraZeneca and 4D MOLECULAR THERAPEUTICS announced the following:
https://www.4dmoleculartherapeutics.com/medimmune-and-4d-molecular-therapeutics-collaborate-to-design-develop-and-commercialize-aav-gene-therapy-for-chronic-lung-disease/
if we read the message carefully,
If we assume that AstraZeneca is our top 10 big pharma within FimaNAc collaboration, then the following might be of interest.
First look at page 24 from Pci Biotech June 2018 presentation. The page has a table with the Nucleic acids successfully delivered by fimaNAC, pay particular attention to the last nucleic acid "AAV vector" (Link: http://pcibiotech.no/wp-content/uploads/2014/01/PCI-Biotech-Company-presentation-June-2018.pdf)
on 10/07/2018 AstraZeneca and 4D MOLECULAR THERAPEUTICS announced the following:
https://www.4dmoleculartherapeutics.com/medimmune-and-4d-molecular-therapeutics-collaborate-to-design-develop-and-commercialize-aav-gene-therapy-for-chronic-lung-disease/
if we read the message carefully,
Redigert 20.01.2021 kl 23:38
Du må logge inn for å svare
Takk.. han kom in som styremedlem i 2018. Hvor er linken ved oppstart med BP? Også han har vart ut av AZ siden 2006. Vet ikke helt om det er linken.
Board Member Professor Andrew Hughes, MD, PhD (born 1964)
AHProfessor Hughes holds an MD from Cambridge, UK, and a PhD degree in behavioural neuroendocrinology. After practicing general clinical medicine in Manchester’s teaching hospitals, he joined Zeneca in 1994. He had roles of growing managerial responsibility in AstraZeneca, including Worldwide Director of Discovery Medicine; Oncology and Infection, Worldwide Clinical Head of Early Phase Oncology, and most recently Global VP of Early Clinical Development. He has been clinical investigator on over 200 clinical trials and leading over 50 research and early clinical development programmes of novel candidate drugs. Currently Professor Hughes holds a position as Strategy Director of the experimental cancer medicine at Manchester Cancer Research Centre, UK. In 2006, he was appointed to a chair of Translational medicine at the University of Manchester, UK. He became a Board member of PCI Biotech Holding ASA in May 2018.
Board Member Professor Andrew Hughes, MD, PhD (born 1964)
AHProfessor Hughes holds an MD from Cambridge, UK, and a PhD degree in behavioural neuroendocrinology. After practicing general clinical medicine in Manchester’s teaching hospitals, he joined Zeneca in 1994. He had roles of growing managerial responsibility in AstraZeneca, including Worldwide Director of Discovery Medicine; Oncology and Infection, Worldwide Clinical Head of Early Phase Oncology, and most recently Global VP of Early Clinical Development. He has been clinical investigator on over 200 clinical trials and leading over 50 research and early clinical development programmes of novel candidate drugs. Currently Professor Hughes holds a position as Strategy Director of the experimental cancer medicine at Manchester Cancer Research Centre, UK. In 2006, he was appointed to a chair of Translational medicine at the University of Manchester, UK. He became a Board member of PCI Biotech Holding ASA in May 2018.
Redigert 20.01.2021 kl 23:38
Du må logge inn for å svare
Dere mener at ´´None ´´. på AAV vector linje til PCIB´s presentation kan betyr AZ ?
Redigert 20.01.2021 kl 23:38
Du må logge inn for å svare
Merlin
24.07.2018 kl 22:41
9427
Board member of PCI Biotech Holding ASA in May 2018.
Med på over 200 kliniske forsøk - velger fyren PCIB!!!!
Med på over 200 kliniske forsøk - velger fyren PCIB!!!!
Redigert 20.01.2021 kl 23:38
Du må logge inn for å svare
Flottesen
24.07.2018 kl 22:45
9415
Jeg tolker det dithen at man mener at AAV per idag ikke har en konkurrerende leveringsmåte i det hele tatt, at PCI er den eneste måten.
At PCIB tolker det dithen, ihvertfall.
At PCIB tolker det dithen, ihvertfall.
Redigert 20.01.2021 kl 23:38
Du må logge inn for å svare
Merlin
24.07.2018 kl 22:46
9411
Ett av verdens flinkeste mennesker sitter i styret til PCIB. Se gjerne dette: http://www.ecmcnetwork.org.uk/news/interviews/interview-prof-andrew-hughes-experimental-cancer-medicine-mres
Redigert 20.01.2021 kl 23:38
Du må logge inn for å svare
Flottesen
24.07.2018 kl 22:58
9374
Vel, nå er det jo ferie, vi får logge av og komme tilbake i August, så kommer det vel kanskje en melding.
Redigert 20.01.2021 kl 23:38
Du må logge inn for å svare
oxion
24.07.2018 kl 23:02
9364
da blåbærplukkinga i år ble tatt av tørken, anbefales å plukke pcib aksjer.
da flere enda har sommersalg...!!!
da flere enda har sommersalg...!!!
Redigert 20.01.2021 kl 23:38
Du må logge inn for å svare
Flottesen
24.07.2018 kl 23:03
9355
..Det er vel uansett ikke urealistisk at BP samarbeidet er vår partner.
Det gir jo litt mening, når det i vår kom en utsettelse for extensions-studien som skulle ledet opp til en pivotal P2 og en partneravtale(eller emisjon). Når resultatene for extension-studien ble llitt utsatt, så ble BP-samarbeidet også forlenget. Litt uventet, det var signalisert at dette samarbeidet skulle "endre karakter" i slutten av Q2, ikke forlenges.
Ingen røyk uten ild, sier man jo.
Det gir jo litt mening, når det i vår kom en utsettelse for extensions-studien som skulle ledet opp til en pivotal P2 og en partneravtale(eller emisjon). Når resultatene for extension-studien ble llitt utsatt, så ble BP-samarbeidet også forlenget. Litt uventet, det var signalisert at dette samarbeidet skulle "endre karakter" i slutten av Q2, ikke forlenges.
Ingen røyk uten ild, sier man jo.
Redigert 20.01.2021 kl 23:38
Du må logge inn for å svare
Merlin
24.07.2018 kl 23:19
9308
>Når resultatene for extension-studien ble litt utsatt, så ble BP-samarbeidet også forlenget.
Eller kanskje normalen?
Eller kanskje normalen?
Redigert 20.01.2021 kl 23:38
Du må logge inn for å svare
oxion
25.07.2018 kl 08:56
9068
da blåbærplukkinga i år ble tatt av tørken, anbefales å plukke pcib aksjer.
da flere enda har sommersalg...!!!
da flere enda har sommersalg...!!!
Redigert 20.01.2021 kl 23:38
Du må logge inn for å svare
bateman
25.07.2018 kl 09:13
9366
Du har et skarpt øye, stockDZ, stå på!
Redigert 21.01.2021 kl 03:30
Du må logge inn for å svare
liang
25.07.2018 kl 10:01
9279
Er det likegyldig hvorledes PCIB legger ut resultatene fra fimaVACC kontra offentliggjøringen av resultatene fra ekstended studien i fimaCHEM for GGK samt løsningen på gjennomføringen/finansieringen på sistnevnte?
Opprinnelig så lå det jo ann til at resultatene i studien i friske frivillige i fimaVACC ville bli gitt markedet før GGK studien for gjentagende behandling.
Kanskje det er "hippsomhapp" hvem som blir gitt til markedet først men en eventuell påfølgende potensiell budrunde for HELE selskapet FØR resultatene for fimaVACC er kjente høres ikke så bra ut.
Uansett løsninger /forhandlinger innen alle 3 forretningsområder så ville jo sterke resultater fra fimaVACC være til fordel for PCIB.
Husker jeg rett så er fimaVACC resultatene sendt til en "ekspertgruppe" for å få råd og veiledning hvorledes bringe fimaVACC videre.
En tar seg vel ikke bryderiet med dette uten at der foreligger "meget" gode resultater tl grunne.
Med alle forbehold , hvem sitter i denne gruppen?
I FimaNAc er det vel et samarbeide mellom PCIB og gjeldende partner som avgjør tid for når resultater legges frem.
Opprinnelig så lå det jo ann til at resultatene i studien i friske frivillige i fimaVACC ville bli gitt markedet før GGK studien for gjentagende behandling.
Kanskje det er "hippsomhapp" hvem som blir gitt til markedet først men en eventuell påfølgende potensiell budrunde for HELE selskapet FØR resultatene for fimaVACC er kjente høres ikke så bra ut.
Uansett løsninger /forhandlinger innen alle 3 forretningsområder så ville jo sterke resultater fra fimaVACC være til fordel for PCIB.
Husker jeg rett så er fimaVACC resultatene sendt til en "ekspertgruppe" for å få råd og veiledning hvorledes bringe fimaVACC videre.
En tar seg vel ikke bryderiet med dette uten at der foreligger "meget" gode resultater tl grunne.
Med alle forbehold , hvem sitter i denne gruppen?
I FimaNAc er det vel et samarbeide mellom PCIB og gjeldende partner som avgjør tid for når resultater legges frem.
Redigert 21.01.2021 kl 03:30
Du må logge inn for å svare
Stock DZ
25.07.2018 kl 11:02
9178
Hi again :)
I found this document that i wants to share with you, this is an investor friendly guide to investing in gene therapy from October 2017, one can only be impressed by the Potential and added value of our FimaNAc program:
Link http://www.fullertreacymoney.com/system/data/files/PDFs/2017/October/12th/rj%20on%20genetics.pdf
PAGE 3:
Talks about market potential for Gene Therapy, it is huge!!
“By our count, there are at least 33 public and 27 private companies developing gene therapy products either by themselves or through partnerships (Exhibits 2 and 3). Collectively, these players are working on one-time solutions for at least 59 diseases, addressing $100+ billion market opportunities, according to our estimates. Given the number of players, the compelling clinical results achieved to date, and the partnerships/deals done in the space, we believe gene therapy is poised to become the next-wave therapeutic category. If we are correct, the current setup of this space is very similar to that seen in the CAR T space, where we just witnessed one of the largest acquisitions of a pre-commercial company (Gilead’s acquisition of Kite for $12 billion) ever”
PAGE 4:
Talks about Gene Therapy Valuation, impressive rate of development
“Arguably, the entire gene therapy space has taken off like a rocket, with the total market capitalization of the companies in our gene therapy index growing from $9.7 billion as of January 1, 2017, to $20.3 billion as of October 6, 2017. Specifically, the gene therapy group generated an average return of approximately 90% year-to-date, outperforming both the NBI (28%) and the S&P500 (14%) (Exhibit 27). Sangamo Therapeutics achieved the highest return of 423%, while Applied Genetic Technologies Corporation (AGTC) was the worst performer so far”
PAGE 21:
Talks about AAV vector as a delivery vehicle that we discussed in this thread earlier:
“AAV vectors are one of the most favorable delivery vehicles for gene therapy largely due to two reasons: 1) the AAV genome contains no expressed genes; therefore, induction of host immunity against the vector is less problematic as compared to adenoviral vectors, except for induction of antibodies that are directed against the AAV capsid (as it flows through the blood stream); and 2) the genomic integration of recombinant AAV vectors occurs at a very low background frequency (0.1 - 0.5%), therefore minimizing the insertional mutagenesis risk with no reported genotoxicity to date"
PAGE 9:
The table shows explicitly that most of the top 10 Big Pharma are using the AAV delivery vehicle for their clinical programs including Pfizer, Bayer, Bristol-Myers Squibb Sanofi …etc and of course we can add to them Astra Zeneca with their latest clinical collaboration with 4D Molecular Therapeutics that we discussed earlier.
My conclusion:
With FimaNAc we are not just sitting on Gold (may be on Rhodium ?). Based on PCI presentation FimaNAc can SUCESSFULLY deliver AAV vector delivery vehicle, which is the most popular for gene therapy's on-going clinical programs. I believe with Pci Biotech strategy to out-license FimaNAc on SEMI-NON exclusive basis gives us the chance to work and collaborate with more and more companies out their including MANY of the top 10 big pharma. The potential for this is HUGE that I can not see where it ends.
Just imagine that FimaNAc would be the KEY for gene therapy efficient delivery where gene therapy business potential is worth 100 billion USD.
I found this document that i wants to share with you, this is an investor friendly guide to investing in gene therapy from October 2017, one can only be impressed by the Potential and added value of our FimaNAc program:
Link http://www.fullertreacymoney.com/system/data/files/PDFs/2017/October/12th/rj%20on%20genetics.pdf
PAGE 3:
Talks about market potential for Gene Therapy, it is huge!!
“By our count, there are at least 33 public and 27 private companies developing gene therapy products either by themselves or through partnerships (Exhibits 2 and 3). Collectively, these players are working on one-time solutions for at least 59 diseases, addressing $100+ billion market opportunities, according to our estimates. Given the number of players, the compelling clinical results achieved to date, and the partnerships/deals done in the space, we believe gene therapy is poised to become the next-wave therapeutic category. If we are correct, the current setup of this space is very similar to that seen in the CAR T space, where we just witnessed one of the largest acquisitions of a pre-commercial company (Gilead’s acquisition of Kite for $12 billion) ever”
PAGE 4:
Talks about Gene Therapy Valuation, impressive rate of development
“Arguably, the entire gene therapy space has taken off like a rocket, with the total market capitalization of the companies in our gene therapy index growing from $9.7 billion as of January 1, 2017, to $20.3 billion as of October 6, 2017. Specifically, the gene therapy group generated an average return of approximately 90% year-to-date, outperforming both the NBI (28%) and the S&P500 (14%) (Exhibit 27). Sangamo Therapeutics achieved the highest return of 423%, while Applied Genetic Technologies Corporation (AGTC) was the worst performer so far”
PAGE 21:
Talks about AAV vector as a delivery vehicle that we discussed in this thread earlier:
“AAV vectors are one of the most favorable delivery vehicles for gene therapy largely due to two reasons: 1) the AAV genome contains no expressed genes; therefore, induction of host immunity against the vector is less problematic as compared to adenoviral vectors, except for induction of antibodies that are directed against the AAV capsid (as it flows through the blood stream); and 2) the genomic integration of recombinant AAV vectors occurs at a very low background frequency (0.1 - 0.5%), therefore minimizing the insertional mutagenesis risk with no reported genotoxicity to date"
PAGE 9:
The table shows explicitly that most of the top 10 Big Pharma are using the AAV delivery vehicle for their clinical programs including Pfizer, Bayer, Bristol-Myers Squibb Sanofi …etc and of course we can add to them Astra Zeneca with their latest clinical collaboration with 4D Molecular Therapeutics that we discussed earlier.
My conclusion:
With FimaNAc we are not just sitting on Gold (may be on Rhodium ?). Based on PCI presentation FimaNAc can SUCESSFULLY deliver AAV vector delivery vehicle, which is the most popular for gene therapy's on-going clinical programs. I believe with Pci Biotech strategy to out-license FimaNAc on SEMI-NON exclusive basis gives us the chance to work and collaborate with more and more companies out their including MANY of the top 10 big pharma. The potential for this is HUGE that I can not see where it ends.
Just imagine that FimaNAc would be the KEY for gene therapy efficient delivery where gene therapy business potential is worth 100 billion USD.
Redigert 21.01.2021 kl 03:30
Du må logge inn for å svare
liang
25.07.2018 kl 11:53
9098
meget godt innlegg DZ
spørsmål:
Er pcib sine partnere under fimaNAc å annse som forløpere for partneravtaler og er isåfall dette for-samarbeidet den vanlige fremgangsmåten?
I så fall , underlig at det er priset til null.
spørsmål:
Er pcib sine partnere under fimaNAc å annse som forløpere for partneravtaler og er isåfall dette for-samarbeidet den vanlige fremgangsmåten?
I så fall , underlig at det er priset til null.
Redigert 21.01.2021 kl 03:30
Du må logge inn for å svare
bateman
25.07.2018 kl 14:16
8985
Very good posts StockDZ, keep up to good work!
Redigert 21.01.2021 kl 03:30
Du må logge inn for å svare
bateman
25.07.2018 kl 18:00
8823
Jeg tror ting kan skje veldig fort i Pcib mtp på at alle tre plattformene står foran en periode med viktige nyheter.
fimaVacc - proof of concept, svar vil kanskje foreligge i løpet av dere kvartalet
fimaChem - safety for dobbel behandling OK? I såfall vil dette kunne være med å booste effekten ytterligere, en megatrigger! Og også effektdata fra dobbelbehandling kan føre til en kursbombe.
Oppstart av PF2 og partner. Håper på en partneravtale som gjør at Pcib kan sette i gang flere studier innenfor fimaChem, tenker da helst H&N, blære og bukspyttkjertelkreft.
fimaNac - Hvis det nå viser seg at det er AZ som er topp 10 BP, og Pcib sitt produkt er nøkkelen til suksess, så tror jeg enten det kan triggebud på hele selskapet eventuelt medføre en enorm oppmerksomhet.
Pcib går en uhyre spennende tid i møte!
fimaVacc - proof of concept, svar vil kanskje foreligge i løpet av dere kvartalet
fimaChem - safety for dobbel behandling OK? I såfall vil dette kunne være med å booste effekten ytterligere, en megatrigger! Og også effektdata fra dobbelbehandling kan føre til en kursbombe.
Oppstart av PF2 og partner. Håper på en partneravtale som gjør at Pcib kan sette i gang flere studier innenfor fimaChem, tenker da helst H&N, blære og bukspyttkjertelkreft.
fimaNac - Hvis det nå viser seg at det er AZ som er topp 10 BP, og Pcib sitt produkt er nøkkelen til suksess, så tror jeg enten det kan triggebud på hele selskapet eventuelt medføre en enorm oppmerksomhet.
Pcib går en uhyre spennende tid i møte!
Redigert 21.01.2021 kl 03:30
Du må logge inn for å svare
Bonusfrelst
25.07.2018 kl 21:15
8659
Gode innlegg Stock!
Redigert 21.01.2021 kl 03:30
Du må logge inn for å svare
Spekulant
25.07.2018 kl 21:36
8611
Fantastisk god graving Stock DZ, det er så spot on at jeg nesten tenker du er i den kantina ;)
Redigert 21.01.2021 kl 03:30
Du må logge inn for å svare
gepard1
25.07.2018 kl 22:04
8542
Det verste av alt, er at alle tre forretningsomraadene kan ta en Genmab hver for seg.
Hvilke forretningsomraade blir solgt foerst?
Hvilke forretningsomraade blir solgt foerst?
Redigert 21.01.2021 kl 03:30
Du må logge inn for å svare
bateman
25.07.2018 kl 22:31
8485
Det et statsmedisteren som har innside fra Radforsk kantinen!;)
Redigert 21.01.2021 kl 03:30
Du må logge inn for å svare
Stock DZ
25.07.2018 kl 23:22
8395
Spekulant
Hehehe ... no I don’t discuss business during lunch time :). Just trying to share my modest homework with you good people.
But I have a happy ending scenario for the kantina play. So when all 3 triggers are met i.e safety for extension study + FimaVacc safety + start of PP2, the market goes ballistic and in that lunch table PW will comment “seems that our shareholders are really enjoying themselves, Susane too although she missed the target price by xxx Kr” then Hans Peter will reply “ now that they are enjoying the “TUNING” so much, Let’s hope they will enjoy the SHOW even more” :)
(This is inspired from the true story of Ravi Shankar for those who don’t know listen to this short audio
https://youtu.be/L9azolYtJhI )
Hehehe ... no I don’t discuss business during lunch time :). Just trying to share my modest homework with you good people.
But I have a happy ending scenario for the kantina play. So when all 3 triggers are met i.e safety for extension study + FimaVacc safety + start of PP2, the market goes ballistic and in that lunch table PW will comment “seems that our shareholders are really enjoying themselves, Susane too although she missed the target price by xxx Kr” then Hans Peter will reply “ now that they are enjoying the “TUNING” so much, Let’s hope they will enjoy the SHOW even more” :)
(This is inspired from the true story of Ravi Shankar for those who don’t know listen to this short audio
https://youtu.be/L9azolYtJhI )
Redigert 21.01.2021 kl 03:30
Du må logge inn for å svare
Stock DZ
27.07.2018 kl 15:51
8028
Hi
Earlier in this thread I stated that "most of the top 10 Big Pharma are using the AAV delivery vehicle for their clinical programs including Pfizer, Bayer, Bristol-Myers Squibb Sanofi …etc and of course we can add to them Astra Zeneca with their latest clinical collaboration with 4D Molecular Therapeutics "
I have also discussed based on Pci biotech presentation that FimaNac can successfully deliver AAV, opening many doors for collaboration agreements.
Here you will find the scientific paper related to PCI Biotech to support this, although this is 2004 paper, it does explain where those Nucleic acids in the table (page 24 PCI June 2018 presentation) successfully delivered by FimaNac come from.
https://www.researchgate.net/publication/8445987_Photochemical_drug_and_gene_delivery
Quote:
"Adeno-associated viruses (AAV) derived from endemic non-patogenic parvoviruses have several properties that make them attractive as vectors in gene therapy[43]. These properties include the absence of host inflammatory response, low cytotoxicity, a low cell-mediated immune response, the ability to transduce non-dividing cells, the induction of long-term gene expression and a broad tropism. A major limitation is the packing constraints of about 5 kbs. PCI has recently been found to increase the transduction efficacy of a serotype 5 AAV in one of two glioblastoma cell lines tested. The non-responding cell line required a much lower number of viral particles to transduce the same number of cells and it was speculated that PCI might improve the transduction efficacy only in cells difficult to transduce by AAV’s [44].
Overall, PCI has the potential of being a very useful technology for in vivo gene delivery, both because it can improve the delivery of genes in general, and because it does this in a light dependent way, rendering the therapeutic gene active only in illuminated sites of the
body. The possibility to use photochemically activated promoters may further add to the specificity of such treatment [45,46]. Thus, by the employment of PCI adverse effects due to expression in non-target areas of, for example a cytotoxic gene could largely be avoided, making PCI especially attractive for gene therapy of cancer and localized diseases."
Earlier in this thread I stated that "most of the top 10 Big Pharma are using the AAV delivery vehicle for their clinical programs including Pfizer, Bayer, Bristol-Myers Squibb Sanofi …etc and of course we can add to them Astra Zeneca with their latest clinical collaboration with 4D Molecular Therapeutics "
I have also discussed based on Pci biotech presentation that FimaNac can successfully deliver AAV, opening many doors for collaboration agreements.
Here you will find the scientific paper related to PCI Biotech to support this, although this is 2004 paper, it does explain where those Nucleic acids in the table (page 24 PCI June 2018 presentation) successfully delivered by FimaNac come from.
https://www.researchgate.net/publication/8445987_Photochemical_drug_and_gene_delivery
Quote:
"Adeno-associated viruses (AAV) derived from endemic non-patogenic parvoviruses have several properties that make them attractive as vectors in gene therapy[43]. These properties include the absence of host inflammatory response, low cytotoxicity, a low cell-mediated immune response, the ability to transduce non-dividing cells, the induction of long-term gene expression and a broad tropism. A major limitation is the packing constraints of about 5 kbs. PCI has recently been found to increase the transduction efficacy of a serotype 5 AAV in one of two glioblastoma cell lines tested. The non-responding cell line required a much lower number of viral particles to transduce the same number of cells and it was speculated that PCI might improve the transduction efficacy only in cells difficult to transduce by AAV’s [44].
Overall, PCI has the potential of being a very useful technology for in vivo gene delivery, both because it can improve the delivery of genes in general, and because it does this in a light dependent way, rendering the therapeutic gene active only in illuminated sites of the
body. The possibility to use photochemically activated promoters may further add to the specificity of such treatment [45,46]. Thus, by the employment of PCI adverse effects due to expression in non-target areas of, for example a cytotoxic gene could largely be avoided, making PCI especially attractive for gene therapy of cancer and localized diseases."
Redigert 21.01.2021 kl 03:30
Du må logge inn for å svare
fabian2
22.07.2019 kl 09:55
6100
Astra Zeneca. De har fått plassert Mr. i ledelsen til PCIB
Redigert 21.01.2021 kl 03:30
Du må logge inn for å svare
fabian2
22.07.2019 kl 10:42
6034
Jeg kan ta feil ........Mr.H.O. er også dypt inne i Bayer
Redigert 21.01.2021 kl 03:30
Du må logge inn for å svare
fabian2
14.11.2019 kl 13:59
5404
Går tilbake til Astra/Zeneca. Jeg er rimelig sikker på at de sitter på alle sider av bordet akkurat nå :)
Redigert 21.01.2021 kl 03:30
Du må logge inn for å svare
fabian2
15.11.2019 kl 00:12
5121
Kun gjennomgang av tilgjengelig informasjon., og egen konklusjon... Da setter jeg Astra som nr. 1 , Roche som nummer 2 , Bayer som nummer 3.
Redigert 21.01.2021 kl 03:30
Du må logge inn for å svare
fabian2
26.11.2019 kl 19:25
4804
Se der ja , egentlig visste jeg ikke annet enn det jeg kunne lese meg til. Altså fornøyd med fabian :)
Redigert 21.01.2021 kl 03:30
Du må logge inn for å svare
fabian2
02.01.2020 kl 21:02
4414
Må bare minne om at Roche har forsøkt å kjøpe AstraZeneca uten å lykkes.
Redigert 21.01.2021 kl 03:30
Du må logge inn for å svare
Computum
02.01.2020 kl 21:48
4300
Regner med at fabian2 er en kortsiktig (uerfaren) trader når jeg ser på hausse-aktiviteten hans på forumet?
Redigert 21.01.2021 kl 03:30
Du må logge inn for å svare
fabian2
07.01.2020 kl 08:18
4076
Feil. Han er CRISPR-behandler blant annet.----Jeg vil ikke si hva jeg "regner med" at Computum er , unngår idiotiske privatkarakteristikker av andre mennesker
Redigert 21.01.2021 kl 03:30
Du må logge inn for å svare
fabian2
08.01.2020 kl 15:22
3911
............1400..........
Redigert 21.01.2021 kl 03:30
Du må logge inn for å svare
Durable
08.01.2020 kl 17:22
3832
Prøver du å fortelle oss noe, fabian2? ;-)
Redigert 21.01.2021 kl 03:30
Du må logge inn for å svare
-
«
- 1
- 2 »